Journal: Nature Communications
Article Title: Galectin-9 binds IgM-BCR to regulate B cell signaling
doi: 10.1038/s41467-018-05771-8
Figure Lengend Snippet: Treatment with exogenous galectin-9 suppresses BCR signaling. a Representative flow cytometric histograms of WT (left) and Gal9-KO (middle) B cells either untreated or treated with various concentrations of recombinant galectin-9 (rGal9; 0.1, 0.2, 0.5, and 1 μM) followed by surface staining for galectin-9 and analyzed using flow cytometry. Overlay of endogenous galectin-9 surface expression in WT cells, and Gal9-KO cells treated with 0.1 μM rGal9 (right). b Naive B cells from WT and Gal9-KO mice treated with 0.1 μM rGal9 were settled onto anti-IgM-coated plates for the indicated time. Cells were lysed and subjected to SDS-PAGE followed by immunoblotting with anti-phospho ERK1/2 and anti-β tubulin (left panel). Quantification of the fold change in pERK over time, averaged over two independent experiments with the mean ± SEM indicated by the bar (right panel). c – f Naive B cells from WT mice were treated with 1 μM rGal9 and settled onto anti-IgM-coated plates for the indicated time. Cells were lysed and subjected to SDS-PAGE followed by immunoblotting with c anti-phosphotyrosine and ERK1/2, d anti-phospho-CD19, e anti-phospho-Akt, and f anti-phospho ERK1/2 and anti-β tubulin. Quantification of the fold change in pCD19, pAkt, and pERK over time, averaged over three independent experiments, with the mean ± SEM indicated by the bar is shown in the right panel. Statistical significance measure by two-way ANOVA followed by Sidak’s multiple comparisons test; **** p < 0.0001, ** p < 0.01, * p < 0.05
Article Snippet: Cells were incubated with 1 μg/mL goat anti-mouse Gal9 (R&D systems, Cat. No. AF3535) in FACS buffer for 1 h at 4 °C.
Techniques: Recombinant, Staining, Flow Cytometry, Expressing, SDS Page, Western Blot